Ningping Zhang

Dr. Ningping Zhang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2021 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YCYanjie Chen
Yanjie Chen
SLShu-Neng Luo
Shu-Neng Luo
LDLing Dong
Ling Dong
TLTao-Tao Liu
Tao-Tao Liu
XSXi-Zhong Shen
Xi-Zhong Shen
LLLiang Li
Liang Li
Background: Since interferon regulatory factor (IRF) family functions in immune response to viral infection, its role in colorectal cancer (CRC) has not been inspected before. This study tries to investigate members of IRF family using bioinformatics approaches in aspect of differential expressions, biological function, tumor immune infiltration and clinical prognostic value for patients with CRC.Methods: Transcriptome profiles data, somatic mutations and clinical information of CRC were obtained from COAD/READ dataset of The Cancer Genome Atlas (TCGA) as a training set. Gene expression data (GSE17536 and GSE39582) were downloaded from the Gene Expression Omnibus as a validating set. A random forest algorithm was used to score the risk for every case. Analyzing gene and function enrichment, constructing protein–protein interaction and noncoding RNA network, identifying hub-gene, characterizing tumor immune infiltration, evaluating differences in tumor mutational burden (TMB) and sensitivity to chemotherapeutics or immunotherapy were performed by a series of online tools and R packages. Immunohistochemical (IHC) examinations were carried out validation in tissue samples.Results: Principal-component analysis (PCA) suggested that the transcript expression levels of nine members of IRF family differed between normal colorectum and CRC. The risk score constructed by IRF family not only acted as an independent factor for predicting survival in CRC patients with different biological processes, signaling pathways and TMB, but also indicated different immunotherapy response with diverse immune and stromal cells infiltration. IRF3 and IRF7 were upregulated in CRC and suggested a shorter survival time in patients with CRC. Differentially expressed members of IRF family exhibited varying degrees of immune cell infiltration. IHC analysis showed a positive association between IRF3 and IRF7 expression and tumor-infiltrating immune cells, including CD4+T cell and CD68+macrophages.Conclusions: On account of differential expression, IRF family members can help to predict both response to immunotherapy and clinical prognosis of patients with CRC. Our bioinformatic investigation not only gives a preliminary picture of the genetic features as well as tumor microenvironment, but it may provide a clue for further experimental exploration and verification on IRF family members in CRC.

27 January 2025 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
SWShu Wei Wong
Shu Wei Wong
YYYong-Yu Yang
Yong-Yu Yang
HCHui Chen
Hui Chen
LXLi Xie
Li Xie
XSXi-Zhong Shen
Xi-Zhong Shen
Jian WuJian Wu
Jian Wu

13 November 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
NZNingping Zhang
Ningping Zhang
RLRanyi Li
Ranyi Li
XLXiao-Yu Li
Xiao-Yu Li
NZNingping Zhang
Ningping Zhang
Immune checkpoint inhibitors (ICIs) significantly improve survival, while immune-mediated hepatotoxicity (IMH) has been reported. To evaluate the incidence and potential risk factors of IMH among cancer patients treated by ICIs, PubMed/Medline, Web of Science, Cochrane, and Embase were searched before 30 March 2024 for systematic review and meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CI) were calculated. Quality assessment was completed using the Newcastle–Ottawa scale. Of 1217 articles identified, 24 consisting of 9076 patients were included, with one study being prospective and the rest retrospective. The overall incidence of any grade IMH and grade ≥ 3 secondary to ICIs was 14% and 7%, respectively. The cholestatic pattern was more prevalent than the hepatocellular and mixed patterns. The meta-analysis revealed that ICI treatment was related to reduced risk of IMH in older patients (SMD: −0.18; 95% CI: −0.33 to −0.04), individuals with higher body mass index (WMD: −2.15; 95% CI: −3.92 to −0.38), males (OR: 0.44; 95% CI: 0.27 to 0.72), and patients with lung cancer (OR: 0.58, 95%CI 0.41 to 0.83). On the other hand, patients with liver metastasis (OR: 1.80; 95% CI: 1.47 to 2.20), history of ICI treatment (OR: 3.09; 95% CI: 1.21 to 7.89), diabetes (OR: 2.19; 95% CI: 1.36 to 3.51), chronic HBV (OR: 3.06; 95% CI: 1.11 to 8.46), and concomitant use of ICIs (OR: 8.73; 95% CI: 2.41 to 31.59) increased the risk of developing IMH. This study will provide clinicians with information on potentially high-risk groups for IMH, who need to be cautiously monitored for liver function when receiving immunotherapy.

5 July 2025 in International Journal of Medical Informatics
Verified
Journal Article
Open access
YWYi Wang
Yi Wang
JLJing Lei
Jing Lei
ZJZhiping Jin
Zhiping Jin
YJYing Jiang
Ying Jiang
NZNingping Zhang
Ningping Zhang
TLTianshu Liu
Tianshu Liu
Immune checkpoint inhibitor (ICI)-related liver injury poses a considerable clinical challenge for cancer patients. This study aimed to develop and validate an interpretable predictive model employing machine learning (ML) algorithms to accurately identify patients at high risk of acute liver injury within one month of initiating ICI treatment. This longitudinal cohort study included pan-cancer patients who received their first ICI treatment between March 2019 and September 2022 at Zhongshan Hospital. Six ML algorithms, namely neural networks (NN), gradient boosting classifier (GBC), eXtreme gradient boosting (XGBoost), logistic regression (LR), categorical boosting classifier (CatBoost) and random forest (RF), were utilized to construct predictive models for acute ICI-related liver injury. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and brier score (BS). The SHapley Additive exPlanations (SHAP) method was applied to rank the feature importance and interpret the final model, providing insights into the contribution of each feature to liver injury prediction, thereby enhancing clinical interpretability. This study is registered with the Chinese Clinical Trial Registry (ChiCTR2300067470). A total of 863 patients were enrolled in the study, with 22.71% experiencing liver injury within one month of ICI initiation. Among the six preliminary models, the RF model exhibited the best performance and was selected for the development of the final model. The SHAP method was utilized to rank variables from the six pre-models, with 10 variables selected for the final model by identifying the intersection of the top 20 most important variables across these models. The final RF model exhibited robust performance, achieving an AUC of 0.81 (95% CI: 0.73-0.90) on the test set, and 0.79 (95% CI: 0.72-0.88) and 0.80 (95% CI: 0.72-0.89) in the 5-fold and 10-fold cross-validation, respectively. The Decision Curve Analysis (DCA) curve illustrated solid clinical benefit, and the calibration curve reflected good predictive consistency. An interpretable RF model was developed to predict acute liver injury occurring within one month after ICI treatment. This clinical-friendly model enables early identification of high-risk patients, facilitating optimized clinical management and ultimately improving treatment outcomes.

5 July 2024 in The FASEB Journal
Verified
Journal Article
Closed access
YWYu‐Li Wang
Yu‐Li Wang
CLChang Liu
Chang Liu
YYYong‐Yu Yang
Yong‐Yu Yang
LZLi Zhang
Li Zhang
XGXiao Guo
Xiao Guo
Jian WuJian Wu
Jian Wu

15 October 2026 in Cancer Medicine
Verified
Journal Article
Open access
JLJing Lei
Jing Lei
YYYiyi Yu
Yiyi Yu
QLQing Liu
Qing Liu
NZNingping Zhang
Ningping Zhang
YWYi Wang
Yi Wang
MLMinzhi Lv
Minzhi Lv
Background: Immune checkpoint inhibitors (ICIs) are increasingly used in patients with gastrointestinal cancer (GIC). However, ICI‐associated adverse event (AE) profiles in GIC remain poorly characterized, and whether AE incidence is associated with clinical outcomes is unclear. Methods: Randomized controlled trials (RCTs) were identified through February 2025. Primary outcomes included treatment‐related AEs (TRAEs) and immune‐related AEs (irAEs) (any grade/Grade 3+). Single‐arm random‐effects meta‐analysis pooled AE incidences; risk ratios (RRs) compared toxicity across ICI regimens. Digitized Kaplan–Meier curves reconstructed survival data for pooled analysis and Cox models. Weighted Spearman's tests assessed correlations between AE incidences and median overall survival (OS)/progression‐free survival (PFS). Results: Forty RCTs enrolling 10,233 patients investigated ICI monotherapy, dual‐ICI therapy, and ICI combination regimens. Pooled any‐grade TRAE incidences were 68.0% (monotherapy, 95% CI: 60%–76%, I 2 = 97.4%, p < 0.001), 87.0% (dual therapy, 95% CI: 73%–100%, I 2 = 98.0%, p < 0.001), and 90.0% (combination therapy, 95% CI: 83%–96%, I 2 = 94.6%, p < 0.001). IrAE incidences reached 24.0% (monotherapy, 95% CI: 18%–29%, I 2 = 67.2%, p < 0.05) and 37.0% (combination therapy, 95% CI: 25%–49%, I 2 = 98.8%, p < 0.001). Relative to monotherapy, dual‐ICI therapy elevated any‐grade (RR = 1.28, 95% CI: 1.05–1.55) and grade ≥ 3 TRAEs (RR = 2.71, 95% CI: 1.84–3.99); ICI combination therapy increased any‐grade (RR = 1.32, 95% CI: 1.15–1.51) and grade ≥ 3 TRAEs (RR = 2.98, 95% CI: 2.30–3.87). Any‐grade TRAEs moderately correlated with median OS ( R = 0.46, p < 0.001) and PFS ( R = 0.50, p < 0.001). Any‐grade irAEs strongly correlated with median OS ( R = 0.90, p < 0.001) and moderately with PFS ( R = 0.57, p < 0.001). Conclusion: While AE incidence is high among GIC patients receiving ICIs, most events are low‐grade. Dual‐ICI and ICI‐based combination therapies carry higher TRAE and irAE risks than monotherapy. At the trial level, higher non‐severe irAE incidence correlated with favorable survival outcomes; this exploratory ecological association does not apply to individual patients. Systematic Review Registration: This study was registered on International Platform of Registered Systematic Review and Meta‐analysis Protocols (INPLASY202230144).